An Evaluation of Clinical Trials and Routine Clinical Practice. Free dinner event, February 24, 2017. Click to Register Today!
An analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
Recent tooth loss and periodontal disease have been linked to primary open-angle glaucoma in a large prospective study of male health professionals.
A new add-on glaucoma module has the capability of creating an anatomic map of each patient’s eye by using two fixed landmarks. The module also includes an extensive reference data base.
Though much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.
Topical cyclosporine may be useful for treating dry eyes associated with immunomodulatory agents like nivolumab, which markedly upregulate T cell activation. In caring for patients with ocular side effects associated with cancer...
Here is your roundup of what made top news in 2016!
LENSAR Inc. announced its filing of a Chapter 11 bankruptcy petition on Dec. 19 to reduce its debt, strengthen its balance sheet, and strengthen its platform for future growth, according to a press release from the company.
Sreedhar Potarazu, MD, an ophthalmologist and entrepreneur from Maryland, recently pled guilty to $30 million in shareholder fraud and and $7.5 million in tax evasion. He was arrested on October 6, 2016.
As the end of the year approaches, we wanted to take a look back at the predictions our Editorial Advisory Board members made for 2016 and see how far we’ve come in the last 12 months.